{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:51:28Z","timestamp":1783608688800,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Major Project of China for the 13th Five-year Plan","award":["2017ZX10202101-001"],"award-info":[{"award-number":["2017ZX10202101-001"]}]},{"name":"National Science and Technology Major Project of China for the 13th Five-year Plan","award":["2018ZX10732101-002"],"award-info":[{"award-number":["2018ZX10732101-002"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CAMS-I2M-1-014"],"award-info":[{"award-number":["CAMS-I2M-1-014"]}]},{"name":"Key Project for Research and Development of Guangdong province","award":["2016B020238002"],"award-info":[{"award-number":["2016B020238002"]}]},{"name":"The 12th Five-Year Major New Drug Discovery Science and Technology","award":["2012ZX09303013"],"award-info":[{"award-number":["2012ZX09303013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Factors predicting peripheral blood total HIV-1 DNA size in chronically infected patients with successfully suppressed viremia remain unclear. Prognostic power of such factors are of clinical significance for making clinical decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two sets of study populations were included: 490 China AIDS Clinical Trial (CACT) participants (Training cohort, followed up for 144 to 288\u2009weeks) and 117 outpatients from Peking Union Medical College Hospital (PUMCH) (Validation cohort, followed up for more than 96\u2009weeks). All patients were chronically HIV-1-infected and achieved successful HIV-1 plasma RNA suppression within week 48. Total HIV-1 DNA in blood at baseline, 12, 24, 48, 96, 144 and 288\u2009weeks after combined antiretroviral therapy (cART) initiation were quantified. Generalized estimating equations and logistic regression methods were used to derive and validate a predictive model of total HIV-1 DNA after 96\u2009weeks of cART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The total HIV-1 DNA rapidly decreased from baseline [median\u2009=\u20093.00 log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/10\n                      <jats:sup>6<\/jats:sup>\n                      peripheral blood mononuclear cells (PBMCs)] to week 24 (median\u2009=\u20092.55 log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/10\n                      <jats:sup>6<\/jats:sup>\n                      PBMCs), and leveled off afterwards. Of the 490 patients who had successful HIV-1 plasma RNA suppression by 96 w post-cART, 92 (18.8%) had a low total HIV-1 DNA count (&lt;\u2009100 copies\/10\n                      <jats:sup>6<\/jats:sup>\n                      PBMCs) at week 96. In the predictive model, lower baseline total HIV-1 DNA [risk ratio (RR)\u2009=\u20090.08, per 1 log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/10\n                      <jats:sup>6<\/jats:sup>\n                      PBMCs,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001] and higher baseline CD4+ T cell count (RR\u2009=\u20091.72, per 100 cells\/\u03bcL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) were significantly associated with a low total HIV-1 DNA count at week 96. In an independent cohort of 117 patients, this model achieved a sensitivity of 75.00% and specificity of 69.52%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline total HIV-1 DNA and CD4+ T cell count are two independent predictors of total HIV-1 DNA after treatment. The derived model based on these two baseline factors provides a useful prognostic tool in predicting HIV-1 DNA reservoir control during cART.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06267-5","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:02:45Z","timestamp":1624334565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yongsong","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuofu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-5675","authenticated-orcid":false,"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"6297","key":"6267_CR1","doi-asserted-by":"publisher","first-page":"aaf6517","DOI":"10.1126\/science.aaf6517","volume":"353","author":"DM Margolis","year":"2016","unstructured":"Margolis DM, Garcia JV, Hazuda DJ, Haynes BF. Latency reversal and viral clearance to cure HIV-1. Science. 2016;353(6297):aaf6517.","journal-title":"Science"},{"key":"6267_CR2","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3389\/fmicb.2019.02878","volume":"10","author":"SD Falcinelli","year":"2019","unstructured":"Falcinelli SD, Ceriani C, Margolis DM, Archin NM. New Frontiers in measuring and characterizing the HIV reservoir. Front Microbiol. 2019;10:2878. https:\/\/doi.org\/10.3389\/fmicb.2019.02878.","journal-title":"Front Microbiol"},{"key":"6267_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.imlet.2018.02.004","volume":"196","author":"K Bashiri","year":"2018","unstructured":"Bashiri K, Rezaei N, Nasi M, Cossarizza A. The role of latency reversal agents in the cure of HIV: a review of current data. Immunol Lett. 2018;196:135\u20139. https:\/\/doi.org\/10.1016\/j.imlet.2018.02.004.","journal-title":"Immunol Lett"},{"issue":"4","key":"6267_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/CMR.00015-16","volume":"29","author":"V Avettand-Fenoel","year":"2016","unstructured":"Avettand-Fenoel V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications. Clin Microbiol Rev. 2016;29(4):859\u201380. https:\/\/doi.org\/10.1128\/CMR.00015-16.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"6267_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1086\/500213","volume":"42","author":"C Goujard","year":"2006","unstructured":"Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis. 2006;42(5):709\u201315. https:\/\/doi.org\/10.1086\/500213.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6267_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1176\/jnp.2009.21.1.68","volume":"21","author":"B Shiramizu","year":"2009","unstructured":"Shiramizu B, Williams AE, Shikuma C, Valcour V. Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci. 2009;21(1):68\u201374. https:\/\/doi.org\/10.1176\/jnp.2009.21.1.68.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"6267_CR7","first-page":"OL581","volume":"50 Online Pub","author":"DA Killebrew","year":"2004","unstructured":"Killebrew DA, Troelstrup D, Shiramizu B. Preferential HIV-1 integration sites in macrophages and HIV-associated malignancies. Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581\u20139.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"6267_CR8","doi-asserted-by":"publisher","first-page":"e03821","DOI":"10.7554\/eLife.03821","volume":"3","author":"JP Williams","year":"2014","unstructured":"Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014;3:e03821. https:\/\/doi.org\/10.7554\/eLife.03821.","journal-title":"Elife."},{"issue":"1","key":"6267_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molmed.2015.11.004","volume":"22","author":"AM Spivak","year":"2016","unstructured":"Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations). Trends Mol Med. 2016;22(1):10\u201327. https:\/\/doi.org\/10.1016\/j.molmed.2015.11.004.","journal-title":"Trends Mol Med"},{"issue":"3","key":"6267_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/QAD.0000000000000953","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016;30(3):343\u201353. https:\/\/doi.org\/10.1097\/QAD.0000000000000953.","journal-title":"AIDS."},{"issue":"19","key":"6267_CR11","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","volume":"369","author":"D Persaud","year":"2013","unstructured":"Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1302976.","journal-title":"N Engl J Med"},{"issue":"3","key":"6267_CR12","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A Saez-Cirion","year":"2013","unstructured":"Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 2013;9(3):e1003211. https:\/\/doi.org\/10.1371\/journal.ppat.1003211.","journal-title":"PLoS Pathog"},{"issue":"1","key":"6267_CR13","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3018(15)00232-5","volume":"3","author":"P Frange","year":"2016","unstructured":"Frange P, Faye A, Avettand-Fenoel V, Bellaton E, Descamps D, Angin M, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV. 2016;3(1):e49\u201354. https:\/\/doi.org\/10.1016\/S2352-3018(15)00232-5.","journal-title":"Lancet HIV"},{"issue":"11","key":"6267_CR14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/cid\/civ171","volume":"60","author":"M Laanani","year":"2015","unstructured":"Laanani M, Ghosn J, Essat A, Melard A, Seng R, Gousset M, et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis. 2015;60(11):1715\u201321. https:\/\/doi.org\/10.1093\/cid\/civ171.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6267_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1473-3099(15)70021-6","volume":"15","author":"A Ch\u00e9ret","year":"2015","unstructured":"Ch\u00e9ret A, Nembot G, M\u00e9lard A, Lascoux C, Slama L, Miailhes P, et al. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infect Dis. 2015;15(4):387\u201396. https:\/\/doi.org\/10.1016\/S1473-3099(15)70021-6.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"6267_CR16","doi-asserted-by":"publisher","first-page":"ofv138","DOI":"10.1093\/ofid\/ofv138","volume":"2","author":"M Ostrowski","year":"2015","unstructured":"Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, et al. Intensifying antiretroviral therapy with raltegravir and maraviroc during early human immunodeficiency virus (HIV) infection does not accelerate HIV reservoir reduction. Open Forum Infect Dis. 2015;2(4):ofv138.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"6267_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/jac\/dks533","volume":"68","author":"L Hocqueloux","year":"2013","unstructured":"Hocqueloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, Legac E, Melard A, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68(5):1169\u201378. https:\/\/doi.org\/10.1093\/jac\/dks533.","journal-title":"J Antimicrob Chemother"},{"issue":"13","key":"6267_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/QAD.0000000000000723","volume":"29","author":"L Cuzin","year":"2015","unstructured":"Cuzin L, Pugliese P, Saune K, Allavena C, Ghosn J, Cottalorda J, et al. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. AIDS. 2015;29(13):1665\u201371. https:\/\/doi.org\/10.1097\/QAD.0000000000000723.","journal-title":"AIDS."},{"issue":"1","key":"6267_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12879-017-2866-y","volume":"17","author":"Y Yue","year":"2017","unstructured":"Yue Y, Wang N, Han Y, Zhu T, Xie J, Qiu Z, et al. A higher CD4\/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study. BMC Infect Dis. 2017;17(1):771. https:\/\/doi.org\/10.1186\/s12879-017-2866-y.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"6267_CR20","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/cid\/ciu086","volume":"58","author":"L Luo","year":"2014","unstructured":"Luo L, Zeng Y, Li T, Lv W, Wang H, Guo F, et al. Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV. Clin Infect Dis. 2014;58(10):1459\u201366. https:\/\/doi.org\/10.1093\/cid\/ciu086.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6267_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/QAI.0000000000000473","volume":"68","author":"Y Li","year":"2015","unstructured":"Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, et al. HIV-1 subtype B\/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China. J Acquir Immune Defic Syndr. 2015;68(3):289\u201397. https:\/\/doi.org\/10.1097\/QAI.0000000000000473.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"6267_CR22","doi-asserted-by":"publisher","first-page":"20659","DOI":"10.7448\/IAS.19.1.20659","volume":"19","author":"J Xie","year":"2016","unstructured":"Xie J, Han Y, Qiu Z, Li Y, Li Y, Song X, et al. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study. J Int AIDS Soc. 2016;19(1):20659. https:\/\/doi.org\/10.7448\/IAS.19.1.20659.","journal-title":"J Int AIDS Soc"},{"issue":"16","key":"6267_CR23","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1097\/QAD.0b013e32833032d4","volume":"23","author":"M Burgard","year":"2009","unstructured":"Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, et al. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients. AIDS. 2009;23(16):2165\u201371. https:\/\/doi.org\/10.1097\/QAD.0b013e32833032d4.","journal-title":"AIDS."},{"issue":"11","key":"6267_CR24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1086\/340521","volume":"185","author":"TW Chun","year":"2002","unstructured":"Chun TW, Justement JS, Pandya P, Hallahan CW, McLaughlin M, Liu S, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis. 2002;185(11):1672\u20136. https:\/\/doi.org\/10.1086\/340521.","journal-title":"J Infect Dis"},{"issue":"9","key":"6267_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cid\/ciu585","volume":"59","author":"GJ Besson","year":"2014","unstructured":"Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014;59(9):1312\u201321. https:\/\/doi.org\/10.1093\/cid\/ciu585.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"6267_CR26","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/cid\/cix192","volume":"64","author":"P Uprety","year":"2017","unstructured":"Uprety P, Patel K, Karalius B, Ziemniak C, Chen YH, Brummel SS, et al. Human immunodeficiency virus type 1 DNA decay dynamics with early, long-term Virologic control of perinatal infection. Clin Infect Dis. 2017;64(11):1471\u20138. https:\/\/doi.org\/10.1093\/cid\/cix192.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6267_CR27","doi-asserted-by":"publisher","first-page":"e1006285","DOI":"10.1371\/journal.ppat.1006285","volume":"13","author":"RT Gandhi","year":"2017","unstructured":"Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, et al. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog. 2017;13(4):e1006285. https:\/\/doi.org\/10.1371\/journal.ppat.1006285.","journal-title":"PLoS Pathog"},{"issue":"5","key":"6267_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0000000000000987","volume":"30","author":"C Hamimi","year":"2016","unstructured":"ULTRASTOP StudyCalin R, Hamimi C, Lambert-Niclot S, Carcelain G, Bellet J, Assoumou L, et al. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS. 2016;30(5):761\u20139.","journal-title":"AIDS."},{"issue":"2","key":"6267_CR29","doi-asserted-by":"publisher","first-page":"ofw100","DOI":"10.1093\/ofid\/ofw100","volume":"3","author":"KE Stephenson","year":"2016","unstructured":"Stephenson KE, Neubauer GH, Bricault CA, Shields J, Bayne M, Reimer U, et al. Antibody responses after analytic treatment interruption in human immunodeficiency virus-1-infected individuals on early initiated antiretroviral therapy. Open Forum Infect Dis. 2016;3(2):ofw100.","journal-title":"Open Forum Infect Dis"},{"issue":"15","key":"6267_CR30","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1097\/QAD.0000000000001195","volume":"30","author":"A Samri","year":"2016","unstructured":"Samri A, Bacchus-Souffan C, Hocqueloux L, Avettand-Fenoel V, Descours B, Theodorou I, et al. Polyfunctional HIV-specific T cells in post-treatment controllers. AIDS. 2016;30(15):2299\u2013302. https:\/\/doi.org\/10.1097\/QAD.0000000000001195.","journal-title":"AIDS."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06267-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:03:34Z","timestamp":1624334614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06267-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6267"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06267-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-92815\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-76673\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"8 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethical Committee of Peking Union Medical College Hospital approved this study and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"592"}}